Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression

Cancer Gene Therapy

Volumn 19, Issue 9, 2012, Pages 619-629

  Zhang, K J ^a   Zhang, J ^b   Wu, Y M ^b   Qian, J ^b   Liu, X J ^b   Yan, L C ^a   Zhou, X M ^b   Xiao, R J ^b   Wang, Y G ^b   Cao, X ^a   Wei, N ^a   Liu, X R ^a   Tang, B ^b   Jiao, X Y ^b   Chen, K ^b   Liu, X Y ^a,b  

^a Chinese Academy of Sciences   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Cancer Targeting Gene Viro Therapy; complete eradication; E1B deletion; hepatoma specificity; IL 24

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; E1A PROTEIN; E1B PROTEIN; INTERLEUKIN 24; ONCOLYTIC ADENOVIRUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER TARGETING GENE VIROTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; ERADICATION THERAPY; FLOW CYTOMETRY; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MOUSE; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; FEMALE; GENE DELETION; GENETIC THERAPY; HEK293 CELLS; HEP G2 CELLS; HUMANS; INTERLEUKINS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 84865211479     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.40     Document Type: Article

References (54)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: S218-S224.
3. Liu XY. A new anticancer strategy: gene-virotherapy therapy of cancer. Chin J Cancer Biother 2001; 8: 1.
4. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13: 481-489.
5. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adeno-viruses for esophageal adenocarcinoma treatment. Cancer Res 2004; 64: 4319-4327.
6. Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
7. Okada Y, Okada N, Nakagawa S, Mizuguchi H, Takahashi K, Mizuno N et al. Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. Jpn J Cancer Res 2002; 93: 436-444.
8. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
9. Sauthoff H, Heitner S, Rom WN, Hay JG. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379-388.
10. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
11. Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, Matsubara S et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882-7888.
12. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663-4670.
13. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007; 12: 52-65.
14. Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD et al. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Therapy 2011; 18: 765-777.
15. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
16. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308.
17. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61: 6428-6436.
18. Arbuthnot P, Bralet MP, Thomassin H, Danan JL, Brechot C, Ferry N. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology 1995; 22: 1788-1796.
19. Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C et al. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996; 7: 1503-1514.
20. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005; 16: 845-858.
21. Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM et al. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma doubleregulated oncolytic adenovirus. Hum Gene Ther 2009; 20: 818-830.
22. Fan JK, Wei N, Ding M, Gu JF, Liu XR, Li BH et al. Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene. Int J Cancer 2010; 127: 707-717.
23. Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006; 13: 1011-1022.
24. Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin 2009; 30: 467-477.
25. Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol 2010; 49: 91-99.
26. Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem 2010; 340: 31-40.
27. Liu XR, Cai Y, Cao X, Wei RC, Li HL, Zhou XM et al. A new oncolytic adenoviral vector carrying dual tumor suppressor genes shows potent antitumor effect. J Cell Mol Med 2011; 16: 1298-1309.
28. Wei RC, Cao X, Gui JH, Zhou XM, Yan QL, Huang WD et al. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Hum Gene Ther 2011; 22: 1109-1119.
29. Liu X, Cao X, Wei R, Cai Y, Li H, Gui J et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther 2011; 19: 49-57.
30. Li B, Liu X, Fan J, Qi R, Bo L, Gu J et al. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J Gene Med 2006; 8: 1232-1242.
31. Narayanan V, Gaudiani JL, Harris RH, Mehler PS. Liver function test abnormalities in anorexia nervosa-cause or effect. Int J Eat Disord 2010; 43: 378-381.
32. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Fut Oncol 2010; 6: 941-949.
33. Schmidt C. Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat Biotechnol 2011; 29: 295-296.
34. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
35. Lei N, Shen FB, Chang JH, Wang L, Li H, Yang C et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther 2009; 16: 33-43.
36. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005; 11: 149-159.
37. Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin Biol Ther 2008; 8: 1633-1643.
38. White E, Cipriani R. Role of adenovirus E1B proteins in transformation: altered organization of intermediate filaments in transformed cells that express the 19-kilodalton protein. Mol Cell Biol 1990; 10: 120-130.
39. White E, Sabbatini P, Debbas M, Wold WS, Kusher DI, Gooding LR. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol Cell Biol 1992; 12: 2570-2580.
40. Subramanian T, Boyd JM, Chinnadurai G. Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins. Oncogene 1995; 11: 2403-2409.
41. Telling GC, Perera S, Szatkowski-Ozers M, Williams J. Absence of an essential regulatory influence of the adenovirus E1B 19-kilodalton protein on viral growth and early gene expression in human diploid WI38, HeLa, and A549 cells. J Virol 1994; 68: 541-547.
42. Schmitz M, Graf C, Gut T, Sirena D, Peter I, Dummer R et al. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa-and fiber-modified replication-competent adenoviruses. Gene Therapy 2006; 13: 893-905.
43. Pan QW, Zhong SY, Liu BS, Liu J, Cai R, Wang YG et al. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacol Sin 2007; 28: 1996-2004.
44. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002; 9: 725-736.
45. Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH et al. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 2006; 17: 379-390.
46. Doloff JC, Waxman DJ, Jounaidi Y. Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther 2008; 19: 1383-1400.
47. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11: 2477-2486.
48. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K et al. Mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002; 99: 10054-10059.
49. Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, Kawabe S et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558-4566.
50. Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239-2243.
51. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002; 168: 6041-6046.
52. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-14039.
53. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther 2004; 9: 510-518.
54. Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki T. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol Cell Biol 1991; 11: 5885-5893.